vs
Side-by-side financial comparison of Old Dominion (ODFL) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.3B, roughly 1.1× Old Dominion). Old Dominion runs the higher net margin — 17.9% vs 10.0%, a 7.9% gap on every dollar of revenue. On growth, Old Dominion posted the faster year-over-year revenue change (-2.9% vs -3.5%). Over the past eight quarters, Organon & Co.'s revenue compounded faster (-4.7% CAGR vs -5.6%).
Old Dominion Freight Line, Inc. (ODFL) is an American regional, inter-regional and national less than truckload shipping (LTL) company. In addition to its core LTL services, the company offers expedited, logistics and household moving services.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
ODFL vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.5B |
| Net Profit | $238.3M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 23.8% | — |
| Net Margin | 17.9% | 10.0% |
| Revenue YoY | -2.9% | -3.5% |
| Net Profit YoY | -6.4% | 67.8% |
| EPS (diluted) | $1.14 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $1.5B | ||
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.4B | $1.6B | ||
| Q2 25 | $1.4B | $1.6B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B |
| Q1 26 | $238.3M | $146.0M | ||
| Q4 25 | $229.5M | $-205.0M | ||
| Q3 25 | $270.9M | $160.0M | ||
| Q2 25 | $268.6M | $145.0M | ||
| Q1 25 | $254.7M | $87.0M | ||
| Q4 24 | $263.1M | $109.0M | ||
| Q3 24 | $308.6M | $359.0M | ||
| Q2 24 | $322.0M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 23.3% | -9.8% | ||
| Q3 25 | 25.7% | 15.2% | ||
| Q2 25 | 25.4% | 14.4% | ||
| Q1 25 | 24.6% | 6.7% | ||
| Q4 24 | 24.1% | 8.1% | ||
| Q3 24 | 27.3% | 13.1% | ||
| Q2 24 | 28.1% | 14.6% |
| Q1 26 | 17.9% | 10.0% | ||
| Q4 25 | 17.6% | -13.6% | ||
| Q3 25 | 19.3% | 10.0% | ||
| Q2 25 | 19.1% | 9.1% | ||
| Q1 25 | 18.5% | 5.8% | ||
| Q4 24 | 19.0% | 6.8% | ||
| Q3 24 | 21.0% | 22.7% | ||
| Q2 24 | 21.5% | 12.1% |
| Q1 26 | $1.14 | $0.55 | ||
| Q4 25 | $1.10 | $-0.78 | ||
| Q3 25 | $1.28 | $0.61 | ||
| Q2 25 | $1.27 | $0.56 | ||
| Q1 25 | $1.19 | $0.33 | ||
| Q4 24 | $1.23 | $0.42 | ||
| Q3 24 | $1.43 | $1.38 | ||
| Q2 24 | $1.48 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $288.1M | — |
| Total DebtLower is stronger | $40.0M | — |
| Stockholders' EquityBook value | $4.4B | — |
| Total Assets | $5.7B | — |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $288.1M | — | ||
| Q4 25 | $120.1M | $574.0M | ||
| Q3 25 | $46.6M | $672.0M | ||
| Q2 25 | $24.1M | $599.0M | ||
| Q1 25 | $97.2M | $547.0M | ||
| Q4 24 | $108.7M | $675.0M | ||
| Q3 24 | $74.2M | $763.0M | ||
| Q2 24 | $104.6M | $704.0M |
| Q1 26 | $40.0M | — | ||
| Q4 25 | $20.0M | $8.6B | ||
| Q3 25 | $65.0M | $8.8B | ||
| Q2 25 | $150.0M | $8.9B | ||
| Q1 25 | $40.0M | $9.0B | ||
| Q4 24 | $40.0M | $8.9B | ||
| Q3 24 | $40.0M | $8.7B | ||
| Q2 24 | $40.0M | $8.7B |
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.3B | $752.0M | ||
| Q3 25 | $4.3B | $906.0M | ||
| Q2 25 | $4.2B | $733.0M | ||
| Q1 25 | $4.2B | $542.0M | ||
| Q4 24 | $4.2B | $472.0M | ||
| Q3 24 | $4.2B | $493.0M | ||
| Q2 24 | $4.1B | $144.0M |
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.5B | $12.9B | ||
| Q3 25 | $5.5B | $13.6B | ||
| Q2 25 | $5.6B | $13.5B | ||
| Q1 25 | $5.5B | $13.2B | ||
| Q4 24 | $5.5B | $13.1B | ||
| Q3 24 | $5.4B | $12.8B | ||
| Q2 24 | $5.3B | $12.2B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.00× | 11.49× | ||
| Q3 25 | 0.02× | 9.74× | ||
| Q2 25 | 0.04× | 12.14× | ||
| Q1 25 | 0.01× | 16.52× | ||
| Q4 24 | 0.01× | 18.81× | ||
| Q3 24 | 0.01× | 17.75× | ||
| Q2 24 | 0.01× | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ODFL
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
